CheckMate 9ER: Long-Term Follow-Up Data

Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.

Related Videos
Experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Related Content